Lantern Pharma Inc.即将推进一项已获欧洲药品管理局（EMA）批准的1B/2期临床试验。这项试验的核心药物是LP-184（即Zirdafulven）。目标人群是经过生物标志物筛选的晚期膀胱癌患者。此举标志着该公司在精准肿瘤学领域迈出了关键一步。试验旨在评估该药物在这一特定患者群体中的疗效与安全性。通过生物标志物的筛选，治疗有望实现更高的精准度。这或将为那些传统疗法效果有限的晚期膀胱癌患者带来新的希望。Lantern Pharma正致力于将LP-184推向临床前沿，以验证其创新潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.